Track topics on Twitter Track topics that are important to you
Biogen is one of 45 public companies in the "Biopharmaceuticals" industry, but how does it contrast to its peers? We will compare Biogen to similar companies based on the strength of its analyst recommendations, dividends, institutional ownership, profitability, earnings, valuation and risk. Biogen currently has a consensus target price of $329.27, suggesting a potential upside of 3.40%.
Original Article: Head to Head Survey: Biogen (BIIB) and Its PeersNEXT ARTICLE
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...